Earnings Feed
Start Free
Home/Insiders/Legorreta Pablo G.
LP
SEC Insider//CIK 0001507678

Legorreta Pablo G.

CIK 00015076783 companiesWINSTON SALEM, NC
SEC Profile

Transactions

50

Companies

3

Filings

11

CIK

0001507678

Recent Transactions

50 trades
  • Award
    PROKIDNEY CORP.$PROK

    Director stock option (right to buy)

    2026-05-28+135,000→ 135,000 total
  • Award
    Royalty Pharma plc$RPRX

    Class A Ordinary Shares

    2026-05-06+143,821→ 1,242,604 total
  • Award
    Royalty Pharma plc$RPRX

    Class A Ordinary Shares

    2026-02-11+157,828→ 1,098,783 total
  • Award
    Royalty Pharma plc$RPRX

    Class A Ordinary Shares

    2025-11-05+36,559→ 940,955 total
  • Gift
    Royalty Pharma plc$RPRX

    LP interests in RPI US Partners 2019, LP

    2025-08-08−60,000→ 692,701 total
  • Award
    Royalty Pharma plc$RPRX

    Class A Ordinary Shares

    2025-08-06+21,901→ 904,396 total
  • Other
    PROKIDNEY CORP.$PROK

    Class A Ordinary Shares

    2025-06-03−3,823,996→ 22,617,909 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Class A Ordinary Shares

    2025-06-03+3,823,996→ 26,441,905 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Common Units in ProKidney LP

    2025-06-03−3,823,996→ 84,283,430 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Class B Ordinary Shares

    2025-06-03−3,823,996→ 84,283,430 total
  • Award
    PROKIDNEY CORP.$PROK

    Director stock option (right to buy)

    2025-05-29+125,862→ 125,862 total
  • Award
    Royalty Pharma plc$RPRX

    Class E Ordinary Shares

    2025-05-16+13,356,742→ 13,356,742 total
  • Other
    Royalty Pharma plc$RPRX

    Option (Right to Buy)

    2025-05-16+857,138→ 857,138 total
  • Other
    Royalty Pharma plc$RPRX

    Class A Ordinary Shares

    2025-05-16+530,348→ 882,495 total
  • Gift
    Royalty Pharma plc$RPRX

    Class B Ordinary Shares

    2025-05-12+867,180→ 0 total
  • Gift
    Royalty Pharma plc$RPRX

    Class B Ordinary Shares

    2025-05-12−867,180→ 0 total
  • Award
    Royalty Pharma plc$RPRX

    Class A Ordinary Shares

    2025-05-08+288,352→ 352,147 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Class B Ordinary Shares

    2025-02-04−532,535→ 88,107,426 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Class A Ordinary Shares

    2025-02-04+532,535→ 23,150,444 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Common Units in ProKidney LP

    2025-02-04−532,535→ 88,107,426 total
  • Other
    PROKIDNEY CORP.$PROK

    Class A Ordinary Shares

    2025-02-04−532,535→ 22,617,909 total
  • Purchase
    PROKIDNEY CORP.$PROK

    Class A Ordinary Shares

    2024-06-13$2.42/sh+22,617,909→ 22,617,909 total
  • Award
    PROKIDNEY CORP.$PROK

    Director stock option (right to buy)

    2024-05-30+62,558→ 62,558 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Class A Ordinary Shares

    2024-02-05+748,952→ 748,952 total
  • Other
    PROKIDNEY CORP.$PROK

    Class A Ordinary Shares

    2024-02-05−748,952→ 0 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Class B Ordinary Shares

    2024-02-05−748,952→ 88,639,961 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Common Units in ProKidney LP

    2024-02-05−748,952→ 88,639,961 total
  • Other
    Royalty Pharma plc$RPRX

    Class A ordinary shares

    2023-11-16−383,000→ 63,795 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Class B Ordinary Shares

    2023-10-30−5,289,055→ 89,388,913 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Class A Ordinary Shares

    2023-10-30+5,289,055→ 5,289,055 total
  • Conversion
    PROKIDNEY CORP.$PROK

    Common Units in ProKidney LP

    2023-10-30−5,289,055→ 89,388,913 total
  • Other
    PROKIDNEY CORP.$PROK

    Class A Ordinary Shares

    2023-10-30−5,289,055→ 0 total
  • Award
    PROKIDNEY CORP.$PROK

    Director stock option (right to buy)

    2023-06-29+48,128→ 48,128 total
  • Purchase
    Royalty Pharma plc$RPRX

    Class A ordinary shares

    2023-06-28$29.51/sh+130,000→ 600,000 total
  • Purchase
    Royalty Pharma plc$RPRX

    Class A ordinary shares

    2023-06-13$32.78/sh+45,000→ 470,000 total
  • Purchase
    Royalty Pharma plc$RPRX

    Class A ordinary shares

    2023-06-12$33.00/sh+45,000→ 425,000 total
  • Purchase
    Royalty Pharma plc$RPRX

    Class A ordinary shares

    2023-05-24$32.25/sh+150,000→ 380,000 total
  • Purchase
    Royalty Pharma plc$RPRX

    Class A ordinary shares

    2023-05-17$32.94/sh+69,612→ 230,000 total
  • Purchase
    Royalty Pharma plc$RPRX

    Class A ordinary shares

    2023-05-16$33.57/sh+160,388→ 160,388 total
  • Gift
    Royalty Pharma plc$RPRX

    ICAI Interests

    2023-05-12+10,269→ 692,701 total
  • Gift
    Royalty Pharma plc$RPRX

    ICAI Interests

    2023-05-12−10,269→ 0 total
  • Gift
    Royalty Pharma plc$RPRX

    Class A ordinary shares

    2022-12-30+292,190.49→ 292,190.49 total
  • Disposition to Issuer
    Epizyme, Inc.

    Restricted Stock Units

    2022-08-12−8,060→ 0 total
  • Gift
    Royalty Pharma plc$RPRX

    LP interests in RPI US Partners 2019, LP

    2022-08-12−150,640→ 2,700,000 total
  • Disposition to Issuer
    Epizyme, Inc.

    Restricted Stock Units

    2022-08-12−8,994→ 0 total
  • Disposition from Tender
    Epizyme, Inc.

    Common Stock, par value $0.0001

    2022-08-12−31,933,334→ 0 total
  • Award
    PROKIDNEY CORP.$PROK

    Earnout Rights

    2022-07-11+10,500,000→ 10,500,000 total
  • Award
    PROKIDNEY CORP.$PROK

    Class B Ordinary Shares

    2022-07-11+94,677,968→ 94,677,968 total
  • Award
    PROKIDNEY CORP.$PROK

    Common Units in ProKidney LP

    2022-07-11+94,677,968→ 94,677,968 total
  • Award
    Epizyme, Inc.

    Stock Option (Right to Buy)

    2022-05-17$0.56/sh+41,006→ 41,006 total

Companies

3

Recent Filings

11

Address

C/O PROKIDNEY CORP 2000 FRONTIS PLAZA BLVD, SUITE 250

WINSTON SALEM, NC, 27103

View on SEC.gov